Product Description
Mechanisms of Action: Immunostimulant
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Chile | China | Germany | Ireland | Italy | New Zealand | Pakistan | Peru | Portugal | Russia | Slovenia | Sweden | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Savara
Company Location: AUSTIN TX 78746
Company CEO: Matthew Pauls
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Japan, Korea, Netherlands, Poland, Portugal, Romania, Spain, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Pulmonary Alveolar Proteinosis
Phase 2: Leg Ulcer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
aPAP | P3 |
Not yet recruiting |
Pulmonary Alveolar Proteinosis |
2027-01-01 |
72% |
SAV00605 | P3 |
Unknown Status |
Pulmonary Alveolar Proteinosis |
2026-12-31 |
|
jRCT2051210036 | P3 |
Recruiting |
Pulmonary Alveolar Proteinosis |
2024-12-31 |
|
IMPALA-2 | P3 |
Active, not recruiting |
Pulmonary Alveolar Proteinosis |
2023-11-30 |